Laura E Dichtel1, Allison Kimball1, Kevin C J Yuen2, Whitney Woodmansee3, Melanie S Haines1, Qiu Xia Guan4, Brooke Swearingen5, Lisa B Nachtigall1, Nicholas A Tritos1, Julie L Sharpless6, Ursula B Kaiser3, Anu V Gerweck4, Karen K Miller1. 1. Neuroendocrine Unit, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA. 2. Swedish Pituitary Center, Swedish Neuroscience Institute, Seattle, WA, USA. 3. Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA. 4. Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA. 5. Department of Neurosurgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA. 6. Department of Endocrinology, University of North Carolina, Chapel Hill, NC, USA.
Abstract
OBJECTIVE: Acromegaly is associated with impaired quality of life (QoL). We investigated the effects of biochemical control of acromegaly by growth hormone receptor antagonism vs somatostatin analog therapy on QoL. DESIGN: Cross-sectional. PATIENTS: 116 subjects: n = 55 receiving a somatostatin analog (SSA group); n = 29 receiving pegvisomant (PEG group); n = 32 active acromegaly on no medical therapy (ACTIVE group). MEASUREMENTS: Acromegaly QoL Questionnaire (AcroQoL), Rand 36-Item Short Form Survey (SF-36) and Gastrointestinal QoL Index (GIQLI); fasting glucose, insulin and IGF-1 levels (LC/MS, Quest Diagnostics). RESULTS: There were no group differences in mean age, BMI or sex [(whole cohort mean ± SD) age 52 ± 14 years, BMI 30 ± 6 kg/m2 , and male sex 38%]. Mean IGF-1 Z-scores were higher in ACTIVE (3.9 ± 1.0) vs SSA and PEG, which did not differ from one another (0.5 ± 0.7 and 0.5 ± 0.7, P < .0001 vs ACTIVE). Eighty-three per cent of PEG previously received somatostatin analogs, which had been discontinued due to lack of efficacy (52%) or side effects (41%). There were no differences in the four QoL primary end-points (AcroQoL Global Score, SF-36 Physical Component Summary Score, SF-36 Mental Health Summary Score and GIQLI Global Score) between SSA and PEG. Higher HbA1c, BMI and IGF-1 Z-scores were associated with poorer QoL in several domains. CONCLUSION: Our data support a comparable QoL in patients receiving pegvisomant vs somatostatin analogs, despite the fact that the vast majority receiving pegvisomant did not respond to or were not able to tolerate somatostatin analogs.
OBJECTIVE: Acromegaly is associated with impaired quality of life (QoL). We investigated the effects of biochemical control of acromegaly by growth hormone receptor antagonism vs somatostatin analog therapy on QoL. DESIGN: Cross-sectional. PATIENTS: 116 subjects: n = 55 receiving a somatostatin analog (SSA group); n = 29 receiving pegvisomant (PEG group); n = 32 active acromegaly on no medical therapy (ACTIVE group). MEASUREMENTS: Acromegaly QoL Questionnaire (AcroQoL), Rand 36-Item Short Form Survey (SF-36) and Gastrointestinal QoL Index (GIQLI); fasting glucose, insulin and IGF-1 levels (LC/MS, Quest Diagnostics). RESULTS: There were no group differences in mean age, BMI or sex [(whole cohort mean ± SD) age 52 ± 14 years, BMI 30 ± 6 kg/m2 , and male sex 38%]. Mean IGF-1 Z-scores were higher in ACTIVE (3.9 ± 1.0) vs SSA and PEG, which did not differ from one another (0.5 ± 0.7 and 0.5 ± 0.7, P < .0001 vs ACTIVE). Eighty-three per cent of PEG previously received somatostatin analogs, which had been discontinued due to lack of efficacy (52%) or side effects (41%). There were no differences in the four QoL primary end-points (AcroQoL Global Score, SF-36 Physical Component Summary Score, SF-36 Mental Health Summary Score and GIQLI Global Score) between SSA and PEG. Higher HbA1c, BMI and IGF-1 Z-scores were associated with poorer QoL in several domains. CONCLUSION: Our data support a comparable QoL in patients receiving pegvisomant vs somatostatin analogs, despite the fact that the vast majority receiving pegvisomant did not respond to or were not able to tolerate somatostatin analogs.
Authors: Michael Buchfelder; Aart-Jan van der Lely; Beverly M K Biller; Susan M Webb; Thierry Brue; Christian J Strasburger; Ezio Ghigo; Cecilia Camacho-Hubner; Kaijie Pan; Joanne Lavenberg; Peter Jönsson; Juliana H Hey-Hadavi Journal: Eur J Endocrinol Date: 2018-12-01 Impact factor: 6.664
Authors: Ritva Kauppinen-Mäkelin; Timo Sane; Harri Sintonen; Helene Markkanen; Matti J Välimäki; Eliisa Löyttyniemi; Leo Niskanen; Antti Reunanen; Ulf-Håkan Stenman Journal: J Clin Endocrinol Metab Date: 2006-07-18 Impact factor: 5.958
Authors: Nienke R Biermasz; Alberto M Pereira; Jan W A Smit; Johannes A Romijn; Ferdinand Roelfsema Journal: J Clin Endocrinol Metab Date: 2005-03-01 Impact factor: 5.958
Authors: Maria P Matta; Elisabeth Couture; Laurent Cazals; Delphine Vezzosi; Antoine Bennet; Philippe Caron Journal: Eur J Endocrinol Date: 2008-03 Impact factor: 6.664